查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916961

腫瘤靶向胜肽市場：按肽類型、作用機制、研發階段、給藥途徑、應用和最終用戶分類－2026-2032年全球預測

Tumor Targeting Peptides Market by Peptide Type, Mechanism, Development Stage, Delivery Route, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腫瘤靶向胜肽市場價值將達到 3.606 億美元，到 2026 年將成長至 3.8509 億美元，到 2032 年將達到 5.705 億美元，年複合成長率為 6.77%。

關鍵市場統計數據
基準年 2025 3.606億美元
預計年份：2026年 3.8509億美元
預測年份 2032 5.705億美元
複合年成長率 (%) 6.77%

本書對腫瘤靶向肽進行了簡潔扼要而又全面的概述，將科學潛力置於一個切合實際的框架內，以便所有相關人員進行轉化研究和實用化。

腫瘤靶向肽結合了分子選擇性和可調控的化學性質，克服了傳統遞送方式難以實現的難題，並正迅速發展成為癌症研究和臨床應用中的精準工具。這些胜肽在診斷、成像和治療領域發揮交叉作用，能夠靶向調控腫瘤微環境，提高惡性病變的顯像效果，並實現細胞毒性或免疫調節有效載荷的靶向遞送。因此，學術界、產業界和臨床領域的各方相關人員正在重新評估其研究重點，以充分利用基於胜肽的平台的獨特優勢，同時應對複雜的研發和監管流程。

技術融合、監管演變和供應鏈韌性將如何重塑腫瘤靶向肽的臨床和商業性路徑

由於技術進步、監管調整和臨床範式的演變，腫瘤靶向肽領域正經歷著變革性的轉變。新型運算設計流程和高通量篩檢平台的出現加速了藥物發現週期，使得建構具有合理平衡的親和性、選擇性和蛋白質水解穩定性的胜肽序列成為可能。偶聯化學和奈米技術的進步使得構建結合成像報告分子和治療載荷的多功能載體成為可能，模糊了診斷和治療之間的傳統界限，並促進了更全面的臨床應用。

評估不斷變化的貿易措施對胜肽腫瘤學供應鏈、生產決策和合作研究的營運和策略影響

2025年推出的關稅和貿易政策變化為腫瘤靶向胜肽生態系統帶來了新的限制和獎勵，其累積影響涵蓋了從原料採購到合作研究以及下游臨床應用等各個方面。進口前驅物、特種試劑和契約製造服務關稅的提高，大幅增加了胜肽合成和偶聯所需關鍵組分的成本。為因應這項變化，各組織加快了供應商多元化策略，同時優先考慮在地採購和國內生產夥伴關係，以保護關鍵工作流程免受貿易波動的影響。

多維細分分析揭示了應用、胜肽化學、作用機制、研發階段、給藥途徑和最終用戶需求如何決定策略重點。

基於細分市場的洞察揭示了不同的技術屬性和應用情境如何影響腫瘤靶向胜肽領域的研發重點和商業性考量。從應用角度來看，診斷應用著重於生物標記篩檢和液態生物檢體功能，這需要高分析靈敏度和可重複的胜肽-標靶相互作用；而成像應用則需要與磁振造影(MRI)、光學成像和正子斷層掃描 (PET) 相容的結構，每種成像方式都對標記、穩定性和藥物動力學提出了特定的要求。治療應用則優先考慮支持免疫療法、放射療法和標靶藥物遞送的機制，這些機制會影響有效載荷的選擇、給藥策略和安全性監測通訊協定。

關鍵區域趨勢和基礎設施差異將有助於開發人員在全球範圍內優先制定測試、製造和市場進入策略。

區域趨勢對腫瘤靶向肽的研發重點、監管趨勢、醫療保健環境和商業化部署至關重要。在美洲，完善的臨床試驗基礎設施和充裕的生物技術資本支持新型胜肽類藥物快速進入早期臨床試驗階段。高水準的專業中心也促進了研究者主導的臨床試驗和產學合作。此外，該地區還擁有重要的監管機構和支付相關人員，這些因素會影響證據產生策略和商業化計劃。

競爭策略與合作模式：平台差異化、注重可製造性以及協作生態系統如何驅動胜肽腫瘤學領域的成功

在腫瘤靶向肽研發領域，各公司之間的競爭行為揭示出幾個反覆出現的策略主題。首先，透過專有胜肽庫、獨特的偶聯化學以及整合的成像和治療模式實現平台差異化，是創造價值和吸引投資者的關鍵所在。能夠展示可重複的從設計到臨床轉換路徑，並利用模組化平台豐富其開發平臺的公司，將在合作和授權談判中擁有比較優勢。

制定可操作的策略重點，以建立平台增強、生產準備、診斷夥伴關係以及基於胜肽的腫瘤解決方案的市場進入途徑。

產業領導者應採取多項切實可行的舉措，以確保腫瘤靶向胜肽計畫的臨床和商業性潛力得以充分發揮。優先投資於模組化平台能力，以實現胜肽序列、成像標記策略和有效載荷偶聯化學的快速迭代。這將加快在多種適應症中獲得證據的速度，並為合作和許可開發創造更多選擇。同時，至關重要的是，從早期開發階段就融入可製造性和品質源於設計 (QbD) 原則，以預見規模化生產面臨的挑戰，確保可靠的供應鏈，並最大限度地減少可能導致監管申報複雜化的批次間差異。

一項綜合性的混合方法研究途徑，結合了專家訪談、監管和專利分析、臨床證據審查以及基於情境的檢驗。

本分析所依據的研究結合了結構化的初步研究、有針對性的二次研究以及嚴謹的三角驗證法，以確保得出可靠且可操作的見解。主要一級資訊來源包括對臨床研究人員、專注於胜肽類藥物的生物技術公司研發總監、合約研發生產機構的高級管理人員以及監管事務專家的深度訪談。這些訪談提供了關於轉化研究障礙、生產限制和臨床試驗設計考量的定性見解，從而為我們對發展趨勢的解釋提供了基礎。

本文綜合分析了科學創新、營運準備和政策趨勢如何共同決定胜肽類腫瘤轉化成功的戰略意義。

總之，腫瘤靶向肽是一類用途廣泛且快速發展的生物醫學工具，可應用於診斷、影像和治療等領域。先進的設計平台、改進的偶聯技術以及策略合作的融合，正在拓展胜肽構建體的轉化應用前景，而監管和報銷方面的考量則持續影響證據要件。近期供應鏈和貿易政策的趨勢凸顯了在地化能力、靈活的採購管道和工藝創新作為科學創新重要補充的價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按肽類型分類的腫瘤靶向肽市場

  • 環肽
  • 線性胜肽
  • 胜肽類似物
  • 自組裝胜肽

9. 按機制分類的腫瘤靶向胜肽市場

  • 主動標靶
  • 被動瞄準

第10章 依研發階段分類的腫瘤標靶胜肽市場

  • 已通過核准的
  • I期試驗
  • II 期研究
  • III期臨床試驗
  • 臨床前階段

11. 依給藥途徑分類的腫瘤標靶胜肽市場

  • 瘤內給藥
  • 靜脈注射
  • 口服
  • 皮下注射

第12章 腫瘤靶向胜肽市場（依應用領域分類）

  • 診斷
    • 生物標記篩檢
    • 液態生物檢體
  • 影像
    • 磁振造影
    • 光學成像
    • 正子斷層掃描
  • 治療藥物
    • 免疫療法
    • 放射治療藥物
    • 標靶藥物遞送

第13章 腫瘤靶向胜肽市場（依最終用戶分類）

  • 診斷中心
  • 醫院
  • 製藥公司
  • 研究所

第14章 腫瘤靶向胜肽市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 腫瘤靶向胜肽市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國腫瘤標靶胜肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國腫瘤靶向胜肽市場

第18章：中國腫瘤靶向胜肽市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics PLC
  • Eli Lilly and Company
  • Ipsen SA
  • Medigene AG
  • Merck & Co., Inc.
  • Novartis AG
  • PeptiDream Inc.
  • Pfizer Inc.
  • Roche Holding AG
Product Code: MRR-AE420CB15421

The Tumor Targeting Peptides Market was valued at USD 360.60 million in 2025 and is projected to grow to USD 385.09 million in 2026, with a CAGR of 6.77%, reaching USD 570.50 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 360.60 million
Estimated Year [2026] USD 385.09 million
Forecast Year [2032] USD 570.50 million
CAGR (%) 6.77%

A concise yet comprehensive orientation to tumor targeting peptides that situates scientific promise within translational and operational realities for stakeholders

Tumor targeting peptides are rapidly maturing as precision tools for oncology research and clinical translation, combining molecular selectivity with adaptable chemistries to address historically intractable delivery challenges. These peptides operate at the intersection of diagnostics, imaging, and therapeutics, enabling targeted modulation of tumor microenvironments, enhanced visualization of malignant lesions, and focused delivery of cytotoxic or immunomodulatory payloads. As a result, stakeholders across academia, industry, and clinical practice are recalibrating research priorities to capture the unique advantages of peptide-based platforms while navigating complex development and regulatory pathways.

In this context, it is essential to understand how peptide type, mechanism of targeting, developmental stage, and administration route shape clinical potential and commercial pathways. Cyclic peptides, linear peptides, peptidomimetics, and self-assembling constructs each present distinct stability, specificity, and manufacturability profiles, while mechanisms such as active targeting through receptor recognition and passive targeting via enhanced permeability and retention effects dictate biodistribution and efficacy. Concurrently, applications span biomarker-driven diagnostics and liquid biopsy workflows, diverse imaging modalities including magnetic resonance imaging, optical imaging, and positron emission tomography, and therapeutic approaches comprising immunotherapy, radiotherapeutics, and targeted drug delivery. This layered landscape requires integrative thinking that aligns scientific rigor with operational feasibility.

Consequently, industry leaders must weigh clinical proof-of-concept evidence alongside pragmatic considerations like scalable synthesis, formulation compatibility for intratumoral, intravenous, oral, or subcutaneous delivery, and the needs of end users ranging from diagnostic centers and hospitals to pharmaceutical companies and research institutes. This introduction outlines the strategic contours of the tumor targeting peptides arena and sets the stage for a deeper exploration of disruptive shifts, policy impacts, segmentation intelligence, regional dynamics, competitive behavior, recommended actions, and the methodological rigor underpinning the associated analysis.

How technological convergence, regulatory evolution, and supply chain resilience are reshaping clinical and commercial pathways for tumor targeting peptides

The landscape for tumor targeting peptides is undergoing transformative shifts driven by converging technological advances, regulatory adaptations, and evolving clinical paradigms. Emerging computational design workflows and high-throughput screening platforms have accelerated discovery cycles, enabling rational engineering of peptide sequences that balance affinity, selectivity, and proteolytic stability. Advances in conjugation chemistries and nanotechnology now permit multifunctional constructs that combine imaging reporters with therapeutic payloads, thereby blurring traditional boundaries between diagnostics and therapeutics and fostering more integrated clinical assets.

Alongside technology, translational pathways are changing as clinical trial designs increasingly emphasize combination regimens and biomarker-stratified populations. This has encouraged developers to align peptide assets with companion diagnostic strategies to improve patient selection and enhance measurable benefit signals. Moreover, regulatory agencies are demonstrating greater receptivity to platform-based evaluation frameworks that can streamline iterative development across related peptide constructs, especially when supported by robust pharmacokinetic, safety, and immunogenicity datasets.

Simultaneously, manufacturing and supply chain resilience have become central considerations; the ability to scale peptide synthesis, ensure consistent quality across batches, and manage cold chain or formulation complexities now factors prominently in go-to-market planning. Cross-sector collaborations between biotech innovators, contract development and manufacturing organizations, clinical research networks, and imaging centers are transforming commercialization roadmaps by enabling shared capabilities and risk distribution. Taken together, these shifts alter strategic priorities for investors, developers, and clinicians, emphasizing integrated pipelines, platform extensibility, and practical manufacturability as decisive drivers of success.

Assessing the operational and strategic repercussions of evolving trade measures on supply chains, manufacturing decisions, and collaborative research in peptide oncology

The introduction of tariffs and trade policy shifts in 2025 imposed a new set of constraints and incentives across the tumor targeting peptide ecosystem, producing cumulative impacts that extend from raw material sourcing to collaborative research and downstream clinical deployment. Increasing duties on imported precursors, specialty reagents, and contract manufacturing services elevated the effective cost base for components central to peptide synthesis and conjugation. In response, organizations accelerated supplier diversification strategies while prioritizing local sourcing and domestic manufacturing partnerships to insulate critical workflows from trade-induced volatility.

At the same time, the tariffs catalyzed operational re-evaluations of global R&D collaborations. Cross-border academic-industry partnerships faced heightened logistical friction and administrative complexity, prompting some consortia to consolidate key experimental activities within fewer jurisdictions or to negotiate contractual terms that account for tariff-related cost variability. This reconfiguration influenced the cadence of multi-site clinical studies, sample shipment protocols for biomarker assays and liquid biopsy workflows, and timelines for technology transfer between originators and contract production partners.

Regulatory interactions were also indirectly affected as authorities and sponsors renegotiated resource allocations to address the combined demands of compliance and cost containment. Developers prioritized assets with clearer regulatory pathways and differentiated clinical value propositions to justify constrained investment bandwidth. Consequently, projects that emphasized platform reproducibility, lower-cost synthesis, or delivery approaches that minimized reliance on imported components gained strategic preference. In parallel, the tariff environment incentivized increased investment in process innovation, such as greener synthesis routes, improved reagent yields, and modular manufacturing approaches that reduce dependence on specialized imported inputs.

Ultimately, while tariffs introduced near-term headwinds, they also stimulated localization, supply chain optimization, and process efficiencies that may confer long-term competitive advantages to organizations that proactively restructured procurement and development models. These adaptations underscore the need for flexible sourcing strategies, robust contractual hedges, and a focus on operational resilience to preserve momentum in peptide therapeutic and diagnostic development amidst shifting trade dynamics.

Multi-dimensional segmentation analysis revealing how application, peptide chemistry, mechanism, development stage, delivery route, and end-user needs dictate strategic priorities

Segmentation-driven insights illuminate how distinct technical attributes and use cases shape development priorities and commercial considerations across the tumor targeting peptide domain. When viewed through the lens of application, diagnostics workstreams emphasize biomarker screening and liquid biopsy capabilities that demand high analytical sensitivity and reproducible peptide-target interactions, whereas imaging applications require constructs compatible with magnetic resonance imaging, optical imaging, or positron emission tomography, each imposing specific labeling, stability, and pharmacokinetic constraints. Therapeutic applications prioritize mechanisms that support immunotherapy, radiotherapeutics, or targeted drug delivery, which in turn influence payload selection, dosing strategies, and safety monitoring protocols.

Peptide type categorization-from cyclic and linear peptides to peptidomimetics and self-assembling peptides-reveals trade-offs between manufacturability, serum stability, and receptor engagement. Cyclic constructs can deliver enhanced conformational rigidity and protease resistance, linear peptides often offer simpler synthetic routes, peptidomimetics provide opportunities to fine-tune bioavailability and target affinity, and self-assembling designs create scaffolds for multivalent display or sustained release. Mechanistically, active targeting approaches that leverage receptor-ligand recognition can enable precise tumor localization at the expense of requiring validated targets and companion diagnostics, while passive targeting strategies rely on physiological phenomena to accumulate agents in tumor tissue and may offer broader applicability across heterogeneous tumor types.

Development stage segmentation underscores the need for stage-appropriate strategies: assets at preclinical phases benefit from robust translational models and scalable synthesis plans, Phase I and II candidates must emphasize safety, pharmacokinetics, and early efficacy biomarkers to de-risk progression, and later-stage or approved products require manufacturing scale-up, post-market surveillance frameworks, and commercialization pathways aligned with healthcare systems. Delivery route considerations-intratumoral, intravenous, oral, and subcutaneous-drive formulation science and clinical protocol design, influencing patient experience, dosing frequency, and infrastructural requirements for administration. Finally, end-user contexts including diagnostic centers, hospitals, pharmaceutical companies, and research institutes determine value propositions and adoption dynamics, with each stakeholder group prioritizing different evidentiary thresholds, procurement constraints, and integration pathways. Integrating these segmentation dimensions provides a nuanced framework for prioritizing investment, aligning translational plans, and tailoring commercial approaches to specific clinical and operational realities.

Key regional dynamics and infrastructural differences that determine where developers prioritize trials, manufacturing, and market access strategies across global territories

Regional dynamics are pivotal in shaping R&D emphasis, regulatory trajectories, reimbursement environments, and commercial rollouts for tumor targeting peptides. In the Americas, established clinical trial infrastructures and deep biotech capital pools support rapid translation of novel peptide constructs into early-stage clinical testing, while high-concentration centers of excellence facilitate investigator-initiated studies and industry-academic collaborations. This region also hosts influential regulatory dialogues and payer stakeholders, which affect evidence generation strategies and commercialization planning.

Within Europe, Middle East & Africa, regulatory plurality and heterogeneous health systems necessitate adaptable value demonstration strategies and region-specific market access pathways. Pan-European clinical networks and collaborative consortia can accelerate multicenter trials, but sponsors must navigate a patchwork of reimbursement criteria and regional procurement mechanisms. Emerging hubs in the Middle East and pockets of innovation across Africa are creating new opportunities for partnerships that combine clinical capacity building with access-driven deployment plans.

Asia-Pacific exhibits diverse innovation ecosystems, with some markets demonstrating rapid adoption of advanced diagnostics and strong biomanufacturing capabilities, while others emphasize cost-effective delivery and local production. Strategic engagement across this region often requires nuanced approaches to intellectual property management, regional manufacturing partnerships, and localization of clinical evidence to meet national regulatory expectations. Across these geographic arenas, differences in peptide manufacturing capacity, imaging infrastructure, and clinical trial access shape where developers prioritize operations, how they structure partnerships, and which evidence packages are necessary to support regional adoption.

Competitive strategies and partnership patterns showing how platform differentiation, manufacturability focus, and collaborative ecosystems drive success in peptide oncology

Competitive behaviors among companies advancing tumor targeting peptides reveal several recurrent strategic themes. First, platform differentiation-whether through proprietary peptide libraries, unique conjugation chemistries, or integrated imaging-therapeutic modalities-serves as a primary axis of value creation and investor interest. Firms that demonstrate repeatable design-to-clinic pathways and that can leverage modular platforms to populate development pipelines secure comparative advantages in partner negotiations and licensing dialogues.

Second, partnerships and ecosystem plays are prevalent; alliances with contract manufacturers, specialized clinical networks, diagnostic developers, and imaging centers enable companies to fill capability gaps without incurring fixed-cost build-outs. This collaborative orientation also accelerates access to complementary expertise for companion diagnostics and enables more streamlined clinical trial execution. Third, attention to manufacturability and regulatory readiness differentiates winners from laggards. Organizations that embed scale-up considerations early-optimizing synthetic routes, addressing analytical method development, and preemptively assessing immunogenicity-reduce downstream friction and compress timelines from proof-of-concept to wider clinical evaluation.

Finally, business models are evolving to include hybrid commercialization strategies that combine direct clinical deployment for specialized indications with out-licensing or co-development agreements for broader therapeutic expansions. As a result, corporate activity reflects a mix of focused biotechs pursuing distinct niches and larger integrators seeking to incorporate peptide-based modules into diversified oncology portfolios. Observing these patterns provides a practical lens for benchmarking competitors and identifying partnership or acquisition targets aligned with strategic capabilities and pipeline synergies.

Actionable strategic priorities for developers to strengthen platforms, manufacturing readiness, diagnostic partnerships, and market access pathways for peptide-based oncology solutions

Industry leaders should pursue several pragmatic actions to ensure their tumor targeting peptide programs realize clinical and commercial potential. Prioritize investment in modular platform capabilities that allow rapid iteration of peptide sequences, labeling strategies for imaging, and payload conjugation chemistries; this reduces time-to-evidence across multiple indications and creates optionality for partnership or licensing outcomes. In parallel, integrate manufacturability and quality-by-design principles early in development to anticipate scale-up challenges, secure reliable supply chains, and minimize batch variability that can complicate regulatory submissions.

Strengthen collaborations across diagnostic and therapeutic stakeholders to co-develop companion assays, harmonize biomarker strategies, and align clinical endpoints that resonate with regulators and payers. Such coordination supports targeted trial enrollment and increases the likelihood of meaningful benefit demonstrations. Additionally, diversify sourcing and establish regional manufacturing contingencies to mitigate trade-related and logistical risks, while investing in process innovations that reduce reliance on constrained imported reagents and high-cost intermediates.

Lastly, cultivate a clear regulatory and market access roadmap that anticipates evidence requirements for reimbursement and post-market surveillance. Engage with regulatory authorities early to validate trial designs and with payers to elucidate value frameworks, ensuring that clinical programs generate outcomes that support adoption. By executing these actions with operational discipline and strategic clarity, organizations can better navigate the complexity of translating peptide technologies into sustainable clinical solutions.

Comprehensive mixed-methods research approach combining expert interviews, regulatory and patent analysis, clinical evidence review, and scenario-based triangulation

The research underpinning this analysis combined structured primary research with targeted secondary intelligence and rigorous triangulation to ensure robust, actionable findings. Primary inputs included in-depth interviews with clinical investigators, R&D leaders at peptide-focused biotechs, senior executives at contract development and manufacturing organizations, and regulatory affairs specialists. These engagements provided qualitative perspectives on translational hurdles, manufacturing constraints, and clinical trial design considerations, informing the interpretation of development-stage dynamics.

Secondary research encompassed peer-reviewed literature on peptide chemistry, recent clinical trial records, regulatory guidance documents relevant to biologics and radiolabeled agents, and patent filings that reveal innovation trajectories. Data synthesis involved cross-validating interview insights with published trial outcomes, manufacturing case studies, and technical white papers to identify consistent patterns. Methodological rigor was maintained through iterative validation workshops with subject-matter experts and by applying conservative inference criteria where direct evidence was limited.

Analytical approaches included segmentation mapping to align technical attributes with application-specific requirements, scenario analysis to explore supply chain and trade policy contingencies, and capability gap assessments to highlight manufacturing and regulatory readiness. Throughout, transparency in assumptions and a documented audit trail of sources supported reproducibility and enabled tailored follow-up research for clients requiring deeper drill-downs into specific peptide chemistries, delivery routes, or regional considerations.

Synthesis of strategic implications showing how scientific innovation, operational readiness, and policy dynamics jointly determine translational success for peptide oncology

In summary, tumor targeting peptides represent a versatile and rapidly evolving class of biomedical tools that bridge diagnostics, imaging, and therapeutic applications. The convergence of advanced design platforms, improved conjugation techniques, and strategic collaborations is expanding the translational runway for peptide constructs, while regulatory and reimbursement considerations continue to shape evidentiary demands. Supply chain and trade policy dynamics introduced in recent years have emphasized the value of localized capabilities, resilient sourcing, and process innovation as essential complements to scientific innovation.

Going forward, success in this domain will favor organizations that integrate early-stage manufacturability planning with clear biomarker strategies, that pursue partnerships to access complementary capabilities, and that build adaptive regulatory roadmaps aligned with regional market access requirements. Translational excellence will depend as much on operational execution and strategic alignment as on molecular innovation. For stakeholders evaluating entry or expansion in this space, the imperative is to couple scientific differentiation with pragmatic implementation plans that address clinical, manufacturing, and commercial realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tumor Targeting Peptides Market, by Peptide Type

  • 8.1. Cyclic Peptides
  • 8.2. Linear Peptides
  • 8.3. Peptidomimetics
  • 8.4. Self Assembling Peptides

9. Tumor Targeting Peptides Market, by Mechanism

  • 9.1. Active Targeting
  • 9.2. Passive Targeting

10. Tumor Targeting Peptides Market, by Development Stage

  • 10.1. Approved
  • 10.2. Phase I
  • 10.3. Phase II
  • 10.4. Phase III
  • 10.5. Preclinical

11. Tumor Targeting Peptides Market, by Delivery Route

  • 11.1. Intratumoral
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Subcutaneous

12. Tumor Targeting Peptides Market, by Application

  • 12.1. Diagnostics
    • 12.1.1. Biomarker Screening
    • 12.1.2. Liquid Biopsy
  • 12.2. Imaging
    • 12.2.1. Magnetic Resonance Imaging
    • 12.2.2. Optical Imaging
    • 12.2.3. Positron Emission Tomography
  • 12.3. Therapeutics
    • 12.3.1. Immunotherapy
    • 12.3.2. Radiotherapeutics
    • 12.3.3. Targeted Drug Delivery

13. Tumor Targeting Peptides Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Hospitals
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Tumor Targeting Peptides Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Tumor Targeting Peptides Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Tumor Targeting Peptides Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Tumor Targeting Peptides Market

18. China Tumor Targeting Peptides Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. Bicycle Therapeutics PLC
  • 19.8. Eli Lilly and Company
  • 19.9. Ipsen S.A.
  • 19.10. Medigene AG
  • 19.11. Merck & Co., Inc.
  • 19.12. Novartis AG
  • 19.13. PeptiDream Inc.
  • 19.14. Pfizer Inc.
  • 19.15. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUMOR TARGETING PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUMOR TARGETING PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SELF ASSEMBLING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ACTIVE TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PASSIVE TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPROVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RADIOTHERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 201. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 226. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 231. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 236. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 241. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL TUMOR TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA TUMOR TARGETING PEPTIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)